T
TVGN
vs
S&P 500
S&P 500
Over the past 12 months, TVGN has underperformed S&P 500, delivering a return of -80% compared to the S&P 500's +14% growth.
Stocks Performance
TVGN vs S&P 500
Performance Gap
TVGN vs S&P 500
Performance By Year
TVGN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tevogen Bio Holdings Inc
Glance View
Tevogen Bio Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Warren, New Jersey. The company went IPO on 2021-11-04. Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The firm is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
